"Certolizumab Pegol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
| Descriptor ID |
D000068582
|
| MeSH Number(s) |
D05.750.741.125 D12.644.541.500.650.250 D12.776.124.486.485.114.224.060.500 D12.776.124.486.485.680.650.250 D12.776.124.790.651.114.224.060.500 D12.776.124.790.651.680.650.250 D12.776.377.715.548.114.224.200.500 D12.776.377.715.548.680.650.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Certolizumab Pegol".
- Chemicals and Drugs [D]
- Macromolecular Substances [D05]
- Polymers [D05.750]
- Polyethylene Glycols [D05.750.741]
- Certolizumab Pegol [D05.750.741.125]
- Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
- Peptide Fragments [D12.644.541]
- Immunoglobulin Fragments [D12.644.541.500]
- Immunoglobulin Fab Fragments [D12.644.541.500.650]
- Certolizumab Pegol [D12.644.541.500.650.250]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
- Immunoglobulin Fragments [D12.776.124.486.485.680]
- Immunoglobulin Fab Fragments [D12.776.124.486.485.680.650]
- Certolizumab Pegol [D12.776.124.486.485.680.650.250]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
- Immunoglobulin Fragments [D12.776.124.790.651.680]
- Immunoglobulin Fab Fragments [D12.776.124.790.651.680.650]
- Certolizumab Pegol [D12.776.124.790.651.680.650.250]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
- Immunoglobulin Fragments [D12.776.377.715.548.680]
- Immunoglobulin Fab Fragments [D12.776.377.715.548.680.650]
- Certolizumab Pegol [D12.776.377.715.548.680.650.250]
Below are MeSH descriptors whose meaning is more specific than "Certolizumab Pegol".
This graph shows the total number of publications written about "Certolizumab Pegol" by people in this website by year, and whether "Certolizumab Pegol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Certolizumab Pegol" by people in Profiles.
-
Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists. Inflamm Bowel Dis. 2017 02; 23(2):254-260.
-
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database Syst Rev. 2016 11 17; 11:CD012437.
-
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016 May 13; (5):CD012183.
-
Intracranial hemorrhage and extensive cerebral venous thrombosis associated with ulcerative colitis. Can J Gastroenterol Hepatol. 2014 Jun; 28(6):299-300.